| Sarah E Citro, PT, DPT | |
|
1212 Route 34 Ste 24-25, Aberdeen, NJ 07747-1903 | |
| (732) 970-7882 | |
| (732) 970-7883 |
| Full Name | Sarah E Citro |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 4 Years |
| Location | 1212 Route 34 Ste 24-25, Aberdeen, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649879263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 40QA01947600 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Proform Physical Therapy Llc | 9436383114 | 15 |
News Archive
Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.
Current knowledge about Parkinson's disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson's Research (MJFF).
Researchers have identified that chemotherapy induces subsequent treatment resistance through damaging healthy tissue, which in turn secretes novel factors that sustain the growth of residual tumor cells.
Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
› Verified 3 days ago
| Entity Name | Proform Physical Therapy Llc |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1073958351 PECOS PAC ID: 9436383114 Enrollment ID: O20131022001577 |
News Archive
Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.
Current knowledge about Parkinson's disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson's Research (MJFF).
Researchers have identified that chemotherapy induces subsequent treatment resistance through damaging healthy tissue, which in turn secretes novel factors that sustain the growth of residual tumor cells.
Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah E Citro, PT, DPT 1212 Route 34 Ste 24-25, Aberdeen, NJ 07747-1903 Ph: (732) 970-7882 | Sarah E Citro, PT, DPT 1212 Route 34 Ste 24-25, Aberdeen, NJ 07747-1903 Ph: (732) 970-7882 |
News Archive
Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.
Current knowledge about Parkinson's disease (PD) does not reflect the diversity of people with the disease, according to The Michael J. Fox Foundation for Parkinson's Research (MJFF).
Researchers have identified that chemotherapy induces subsequent treatment resistance through damaging healthy tissue, which in turn secretes novel factors that sustain the growth of residual tumor cells.
Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
› Verified 3 days ago